Journal of Translational Medicine,
Journal Year:
2024,
Volume and Issue:
22(1)
Published: Oct. 31, 2024
Hyperuricemia
is
independently
associated
with
a
poor
prognosis
in
patients
myocardial
infarction
(MI).
Furthermore,
MI
induces
activation
of
the
repair
response
local
fibroblasts,
resulting
extracellular
matrix
accumulation
that
generates
stable
fibrotic
scar
infarcted
area.
However,
researchers
have
not
determined
whether
hyperuricemia
affects
fibroblast
and
its
involvement
postinfarction
cardiac
remodeling.
Hyperuricemia
(HUA)
is
a
globally
prevalent
metabolic
disease
characterized
by
excessive
production
or
insufficient
excretion
of
uric
acid
in
the
serum.
Although
several
drugs
are
available
for
treatment
HUA,
they
have
been
associated
with
undesirable
side
effects.
Therefore,
this
study
aims
to
evaluate
therapeutic
effects
sunflower
head
extract
(KHE)
on
HUA
mouse
model
and
explore
its
potential
mechanisms.
All
mice
were
randomly
divided
into
three
groups:
Normal
control
(NC,
0.5%
CMC-Na),
(MD,
yeast
paste
20
g/kg),
KHE
group
(KHE,
1
g/kg).
Biochemical
indicators,
oxidative
stress
state,
metabolomics
analyzed.
reduced
levels
5-aminoimidazole
ribonucleotide,
xanthine,
hypoxanthine,
serum
but
increased
adenine
taurine.
decreased
activities
superoxide
dismutase
(SOD)
enzymes,
hepatic
hydrogen
peroxide
(H2O2)
malondialdehyde
(MDA)
levels,
betaine
aldehyde
beta-D-glucosamine.
improved
mitigated
damage
kidneys
joints
caused
urate
deposition.
These
findings
provide
comprehensive
evidence
supporting
anti-HUA
underlying
mechanisms
mice.
Journal of Orthopaedic Surgery and Research,
Journal Year:
2025,
Volume and Issue:
20(1)
Published: April 1, 2025
MicroRNA
(miRNA)
participates
in
the
pathophysiological
processes
of
multiple
metabolic
diseases,
including
gout.
In
gout
patients,
there
is
concomitant
derangement
bone
metabolism.
The
study
aimed
to
explore
correlation
different
ultrasonic
manifestations
and
miR-328-3p
levels
with
markers
patients.
A
total
320
patients
were
grouped
according
musculoskeletal
ultrasound
(MSUS)
imaging.
Serum
osteocalcin
(BGP),
C-terminal
telopeptide
type
I
collagen
(CTX-I)
osteopotin
(OPN)
detected
evaluate
via
qRT-PCR.
Pearson's
analysis
was
performed
relationships
between
variables.
Patients
tophi
accompanied
by
erosion
demonstrated
significantly
elevated
BGP
OPN
compared
those
or
aggregate
MSU
crystals
absence
erosions.
Cases
long
course
disease
exhibited
more
severe
destruction.
without
specific
clinical
presented
highest
serum
miR-328-3p,
whereas
erosions
lowest
values.
Significantly
negative
correlations
also
for
values
all
associated
diverse
MSUS
imaging
are
capable
reflecting
joint
impairment
ACS Applied Nano Materials,
Journal Year:
2024,
Volume and Issue:
7(9), P. 9816 - 9846
Published: April 22, 2024
Gout
is
an
inflammatory
arthropathy
resulting
from
the
deposition
of
monosodium
urate
crystals
in
and
around
joints,
triggering
release
pro-inflammatory
cytokines.
Some
key
principles
for
managing
gout
are
encompassing
comorbidity
screening,
flare
treatment,
urate-lowering
therapy,
anti-inflammatory
prophylaxis.
One
major
concerns
with
treatment
side
effects
drug
due
to
uncontrolled
biodistribution.
Nanocarrier
systems
utilized
surmount
limitations
current
drugs,
including
not
only
biodistribution
issues
but
also
stability
bioavailability
drugs.
Nanocarriers
as
promising
delivery
can
effectively
deliver
drugs
by
specifically
targeting
inflamed
tissues
through
enhanced
permeability
retention
effect
mediated
delivery.
Notable
examples
include
liposomes,
niosomes,
ethosomes,
transfersomes,
solid
lipid
nanoparticles,
polymeric
nanoemulsions,
liquid
crystalline
namely,
cubosomes,
hexosomes,
spongosomes.
These
nanocarriers
hold
great
promise
vehicles
transporting
poorly
therapeutic
agents
precise
target
sites,
associated
controlled
capabilities
bolster
bioavailability.
Preclinical
studies
have
demonstrated
efficacy
nanocarrier-based
therapies
reducing
inflammation
tissues,
inhibiting
crystal
formation,
improving
joint
function
animal
models
gout.
In
this
review,
we
explore
main
nanocarrier
systems,
their
respective
advantages
drawbacks,
emphasize
role
nanoformulations
advancing
treatment.
The
encapsulation
active
within
therapy
represents
a
significant
advancement
pharmaceutical
area
nanomedicine
application
succeed
overall
context
near
future.
Journal of Medicinal Chemistry,
Journal Year:
2024,
Volume and Issue:
67(22), P. 19966 - 19987
Published: Nov. 8, 2024
Increased
biosynthesis
or
underexcretion
of
uric
acid
(UA
urate)
in
the
body
ultimately
leads
to
development
hyperuricemia.
Epidemiological
studies
indicate
that
hyperuricemia
is
closely
associated
with
occurrence
various
diseases
such
as
gout
and
cardiovascular
diseases.
Currently,
first-line
therapeutic
medications
used
reduce
UA
levels
primarily
include
xanthine
oxidase
(XO)
inhibitors,
which
limit
production,
urate
transporter
1
(URAT1)
decrease
reabsorption
enhance
excretion.
Despite
significant
progress
urate-lowering
therapies,
long-term
use
these
drugs
can
cause
hepatorenal
toxicity
well
complications.
Therefore,
there
an
urgent
need
for
novel
anti-hyperuricemic
agents
better
efficacy
lower
toxicity.
This
perspective
mainly
focuses
on
current
research
design
strategy
agents,
particularly
those
targeting
XO
URAT1.
It
our
hope
this
will
provide
insights
into
challenges
opportunities
drug
discovery.
